TB-500: The Heart-Repair Protein Behind the Peptide

Researchers blocked an artery feeding rats' hearts, then treated some of the animals with a protein called thymosin beta-4. Four weeks later, the treated group had 43% less damaged heart tissue by the study's tissue measurements.

That result helps explain the interest in TB-500. The peptide identified under that name contains a short section of thymosin beta-4, a protein involved in cell movement and repair. The heart experiment used the full protein.

A later experiment in pigs found no significant heart protection. The two studies used different injuries and treatment schedules. Reading them together helps explain what a repair peptide would have to accomplish.

This is episode 5 of 30 Peptides.

A healing wound needs living cells at the right location. Cells around the injury change shape and move. Blood-vessel cells can extend into areas that need a supply of oxygen and nutrients. Several processes have to work together before damaged tissue can function again.

Inside a cell, a protein called actin helps form the fibers used for shape and movement. Those fibers can assemble and come apart as the cell changes what it is doing. Thymosin beta-4 binds the individual actin units and helps control the pool available for that assembly.

That puts it close to a basic part of repair. Researchers have also studied its effects on signals that help injured cells survive. A treatment that keeps more cells alive early in an injury could leave less damage for the body to repair later.

The full thymosin beta-4 molecule contains 43 amino acids, the small units that make up proteins. Different sections contribute to its activity. TB-500 entered the discussion because a short section of this molecule had drawn interest as a peptide in its own right.

The heart experiment tested whether that biology could preserve tissue after a major injury.

In the 2013 study, Weike Bao and colleagues tied off a coronary artery in rats. This cuts blood flow to part of the heart, producing a defined area of injury. The researchers could then compare hearts exposed to the same type of damage.

One group received the control solution. A second received full-length thymosin beta-4 for the first three days. A third started on the same schedule and continued treatment every third day through day 28. Treatment began immediately after the artery was blocked.

At four weeks, the team examined tissue sections from the hearts. They measured the damaged area in several cross-sections to estimate infarct volume, the portion of the heart affected by tissue death.

The control group averaged 9.1% by that measurement. The prolonged-treatment group averaged 5.2%. The difference was statistically significant.

The familiar 43% figure describes the relative reduction from 9.1 to 5.2. In absolute terms, the gap was 3.9 percentage points. Both numbers describe the same finding; the denominator tells you how large it was.

The shorter course produced a smaller reduction that did not reach statistical significance. That makes the treatment schedule part of the result. The successful arm received repeated treatment over the period when the injured heart was changing.

A smaller damaged region is an important result. It suggests that treatment preserved tissue or changed how the injury developed. The measurements cannot tell us that the rats grew an entirely new section of working heart muscle.

The researchers also measured how well the hearts pumped.

The study also measured pressure inside the heart and how quickly that pressure changed during contraction and relaxation. Several of those measurements improved with prolonged treatment.

Another familiar measure is ejection fraction: the share of blood in a filled heart chamber that gets pumped out with each beat. It gives researchers a way to assess the heart as a working pump.

Average ejection fraction was 47.4% in the control group and 52.4% in the prolonged-treatment group. That difference did not reach statistical significance in this experiment.

So the strongest result here was the tissue measurement, supported by improvements in some pressure measurements. The experiment did not establish a reliable improvement in every measure of heart function.

The distinction matters for any recovery claim. A photograph can show that a wound has closed. A tissue section can show less injury. A strength test asks whether the repaired structure can do its job under load. Each measurement answers a different question.

If your goal is to return to running after an injury, the useful outcome will eventually involve the ability to run and tolerate training. A change in a cell signal is an earlier step in that chain of evidence.

The rat study gave researchers a reason to keep testing thymosin beta-4. The next question was how broadly the protection would hold across injuries and treatment conditions.

In 2016, Christoffer Stark and colleagues tested full-length thymosin beta-4 in pigs undergoing a procedure designed to model open-heart surgery.

The animals went on a heart-lung machine. Their hearts were stopped with a protective solution while blood flow through the heart was interrupted, then circulation was restored. This produces injury across the heart under conditions quite different from permanently tying off one artery.

The researchers gave thymosin beta-4 by intravenous infusion before the procedure and again afterward. They followed the animals for about 30 hours and examined heart function, blood flow, and cell injury.

The treatment did not produce a significant protective effect in this model.

The experiment was small. Ten pigs entered it; two in the treatment group died before completion, leaving four animals in each group for the planned final measurements. The study was not designed to establish an effect on survival, and the authors could not attribute those deaths to treatment.

There were several differences from the rat experiment. The injury affected the heart differently, treatment entered through a vein, and follow-up covered hours instead of weeks. The team measured increased levels of the peptide in blood, but did not measure its concentration inside the heart tissue.

That leaves a concrete delivery question. Enough peptide in the bloodstream does not by itself tell us how much reached the cells where it needed to act.

These studies locate a promising effect under specific conditions. The rat result supports further work on tissue protection. The pig result shows why the route, timing, and type of injury need their own tests before that effect can be expected elsewhere.

A separate 2012 study approached TB-500 through chemistry. Belgian customs had confiscated a package bearing that name, and researchers at Ghent University analyzed its contents.

They identified a peptide containing seven amino acids, with the sequence LKKTETQ. It matched positions 17 through 23 within the 43-amino-acid thymosin beta-4 molecule. An acetyl group was attached at one end, so the complete chemical shorthand was Ac-LKKTETQ.

The team made a matching peptide and used laboratory measurements to confirm the identity. The full-length protein used in the heart experiments was absent from the tested preparation.

This was one product analysis. It gives us a precise identity for that sample and a reason to check what later authors mean when they use the name TB-500. It cannot establish the contents of every product sold under that name today.

The section identified in TB-500 overlaps an area of the full protein involved in actin binding. That offers a biological reason to study it. A fragment still needs experiments that test its own effects, because removing the rest of a protein changes the molecule being administered.

The heart papers above studied the full 43-amino-acid protein. Their numerical results belong to that molecule, in those experiments. A claim about the seven-amino-acid fragment needs a study of the fragment.

This is a useful habit throughout peptide research. When two names appear to refer to the same treatment, find the sequence or the methods section before joining their evidence together.

When you next see a TB-500 recovery claim, open the linked paper and start with what the animals or people received. The methods should identify the molecule. If the paper says thymosin beta-4, check whether it used the full protein or a named fragment.

Then find the actual injury and treatment route. A topical treatment on an open wound answers a different delivery question from an injection intended to reach a tendon. Those details determine how far you can carry the result.

Spend the most time on the outcome that matters to you. If the claim is faster return to sport, look for a measured return to sport. If the paper reports tissue preservation, keep that result in its own terms. It can be valuable while leaving later questions open.

For the heart study in this article, the useful statement is clear: prolonged treatment with full-length thymosin beta-4 reduced the measured damaged portion of rat hearts from 9.1% to 5.2%. Some measures of heart function improved, while ejection fraction did not show a significant difference. A different pig injury model found no significant protection.

TB-500 adds another question to this research: how much of the full molecule's activity can that short sequence reproduce? Testing the fragment directly could show which repair effects it retains and where the rest of the protein matters.

Reply with the recovery outcome you want examined in this series. A specific injury or activity will help focus a future issue on the evidence that matters to you.

Next is MOTS-c, a peptide encoded by mitochondrial DNA, with an unusual connection to exercise. New issues arrive Monday, Wednesday, and Friday.

1. Bao W et al. Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury. Frontiers in Pharmacology, 2013. 2. Stark CKJ et al. Systemic dosing of thymosin beta 4 before and after ischemia does not attenuate global myocardial ischemia-reperfusion injury in pigs. Frontiers in Pharmacology, 2016. 3. Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis, 2012. Author manuscript.

For entertainment and education only. Not medical advice. Talk to your doctor before starting anything.